Takeda Pharmaceutical Company Limited (NYSE:TAK) does about 2.89M shares in volume on a normal day but saw 3251792 shares change hands in Monday trading. The company now has a market cap of 50.70B USD. Its current market price is $16.19, marking a decrease of -0.49% compared to the previous close of $16.27. The 52 week high reached by this stock is $16.30 whilst the lowest price level in 52 weeks is $12.28. The script in recent trading has seen the stock touch a high of $16.295 and a low of $16.09.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Takeda Pharmaceutical Company Limited (TAK) has a 20-day trading average at $15.74 and the current price is -0.67% off the 52-week high compared with 31.84% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.01 and its 200-day simple moving average is $14.16. If we look at the stock’s price movements over the week, volatility stands at 1.08%, which increases to 1.14% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 69.26 to suggest the stock is neutral.
The consensus objective for the share price is $17.63, suggesting that the stock has a potential upside of 8.17% over the period.
FactSet Research has provided data showing that 14 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 5 analysts have rated it as a buy and 7 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 19, 2022 when Cowen upgraded the stock to “Outperform” and issued a price target of between $21 and $24.
The current price level is 3.15%, 8.24%, and 14.37% away from its SMA20, SMA50, and SMA200 respectively, with the TAK price moving above the 50-day SMA on January 23. Takeda Pharmaceutical Company Limited (TAK) stock is up 0.56% over the week and 5.61% over the past month. Its price is 3.78% year-to-date and 12.43% over the past year.
The company’s next earnings report is expected on 05/11/2023.
Its 12-month price target is $16.32. To reach the target analysts have set, the stock logically needs to grow 8.17 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $13.56, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $25.52.
Outstanding shares total 3.10B with insiders holding 0.01% of the shares and institutional holders owning 1.89% of the company’s common stock. The company has a return on investment of 3.90% and return on equity of 3.50%. The price to earnings ratio (P/E ratio) amounts to 30.38. The beta has a value of 0.68. Price to book ratio is 0.96 and price to sales ratio is 1.74.
